Qin Lin

List of Publications by Year
in descending order

116 papers	3,526 citations	218592 26 h-index	175177 52 g-index
120 all docs	120 docs citations	120 times ranked	2954 citing authors

#	Article	IF	Citations
1	Increased 68Ga-FAPI Uptake in the Pulmonary Cryptococcus and the Postradiotherapy Inflammation. Clinical Nuclear Medicine, 2022, 47, 243-245.	0.7	10
2	Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of ⁶⁸Ga-Labeled FAPI Dimer. Journal of Nuclear Medicine, 2022, 63, 862-868.	2.8	59
3	Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1322-1337.	3.3	49
4	Somatostatin receptor imaging with [68Ga]Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1360-1373.	3.3	7
5	Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review. Theranostics, 2022, 12, 1557-1569.	4.6	61
6	Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncology, The, 2022, 23, 209-219.	5.1	87
7	Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer. JAMA Network Open, 2022, 5, e220120.	2.8	25
8	Olanzapine 5â€‰mg for Nausea and Vomiting in Patients with Nasopharyngeal Carcinoma Receiving Cisplatin-Based Concurrent Chemoradiotherapy. Journal of Oncology, 2022, 2022, 1-7.	0.6	1
9	Toripalimab plus chemotherapy in treatment-naÃ¯ve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell, 2022, 40, 277-288.e3.	7.7	177
10	Adjuvant radiotherapy shows benefit in selected stage I uterine sarcoma: A risk scoring system based on a population analysis. Cancer Medicine, 2022, 11, 2846-2854.	1.3	2
11	A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Antiâ€“PD-L1 mAb Combination to Enhance the Antitumor Effect. Clinical Cancer Research, 2022, 28, 2923-2937.	3.2	12
12	FAP-targeted radionuclide therapy with [177Lu]Lu-FAPI-46 in metastatic nasopharyngeal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1767-1769.	3.3	16
13	Virusâ€Inspired Hollow Mesoporous Gadoliniumâ€Bismuth Nanotheranostics for Magnetic Resonance Imagingâ€Guided Synergistic Photodynamicâ€Radiotherapy. Advanced Healthcare Materials, 2022, 11, e2102060.	3.9	8
14	Decision-making about mastectomy among Chinese women with breast cancer: a mixed-methods study protocol. BMJ Open, 2022, 12, e054685.	0.8	1
15	Selfâ€Delivering Nanodrugs Developed via Smallâ€Moleculeâ€Directed Assembly and Macrophage Cloaking for Sonodynamicâ€Augmented Immunotherapy. Advanced Healthcare Materials, 2022, 11, e2102770.	3.9	5
16	Rational Design and Pharmacomodulation of Protein-Binding Theranostic Radioligands for Targeting the Fibroblast Activation Protein. Journal of Medicinal Chemistry, 2022, 65, 8245-8257.	2.9	21
17	Noninvasive Diagnosis of Nasopharyngeal Carcinoma Based on Phenotypic Profiling of Viral and Tumor Markers on Plasma Extracellular Vesicles. Analytical Chemistry, 2022, 94, 9740-9749.	3.2	9
18	Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 73-86.	3.3	153

#	Article	IF	Citations
19	Comparison of ⁶⁸Ga-FAPI and ¹⁸F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers. Radiology, 2021, 298, 393-402.	3.6	171
20	Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1349-1358.	0.4	35
21	Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1604-1617.	3.3	100
22	Cardiac angiosarcoma detected using 68Ga-fibroblast activation protein inhibitor positron emission tomography/magnetic resonance. European Heart Journal, 2021, 42, 1276-1276.	1.0	6
23	A novel predict factor that increases the success rate of methotrexate treatment in fallopian tube pregnancy. Annals of Translational Medicine, 2021, 9, 146-146.	0.7	3
24	Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1944-1955.	3.3	75
25	Chemotherapy Plus Radiotherapy Versus Radiotherapy in Patients With Small Cell Carcinoma of the Esophagus: A SEER Database Analysis. Cancer Control, 2021, 28, 107327482198932.	0.7	4
26	A COVID-19 risk score combining chest CT radiomics and clinical characteristics to differentiate COVID-19 pneumonia from other viral pneumonias. Aging, 2021, 13, 9186-9224.	1.4	11
27	Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3606-3617.	3.3	50
28	X-ray-Activated Simultaneous Near-Infrared and Short-Wave Infrared Persistent Luminescence Imaging for Long-Term Tracking of Drug Delivery. ACS Applied Materials & Interfaces, 2021, 13, 16166-16172.	4.0	26
29	68Ga-fibroblast activation protein inhibitor PET/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer. Radiotherapy and Oncology, 2021, 158, 55-61.	0.3	36
30	Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet, The, 2021, 398, 303-313.	6.3	98
31	Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study. Journal of Clinical Oncology, 2021, 39, 3273-3282.	0.8	48
32	Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1396-1406.	0.4	14
33	Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2021, 22, 1162-1174.	5.1	185
34	New-generation photosensitizer-anchored gold nanorods for a single near-infrared light-triggered targeted photodynamicâ€“photothermal therapy. Drug Delivery, 2021, 28, 1769-1784.	2.5	7
35	436â€…A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy. , 2021, 9, A466-A466.		6
36	Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study). , 2021, 9, e003790.		36

#	Article	IF	Citations
37	Usefulness of [18F]fluorodeoxyglucose PET/CT for evaluating the PD-L1 status in nasopharyngeal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1065-1074.	3.3	23
38	A FDG-PET radiomics signature detects esophageal squamous cell carcinoma patients who do not benefit from chemoradiation. Scientific Reports, 2020, 10, 17671.	1.6	19
39	GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/ unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Translational Lung Cancer Research, 2020, 9, 2008-2015.	1.3	10
40	Cognitive dysfunction in patients with nasopharyngeal carcinoma after induction chemotherapy. Oral Oncology, 2020, 111, 104921.	0.8	6
41	Prognostic factors and treatment comparison in small cell neuroendocrine carcinoma of the uterine cervix based on population analyses. Cancer Medicine, 2020, 9, 6524-6532.	1.3	21
42	Prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients. PLoS ONE, 2020, 15, e0236841.	1.1	15
43	Prognostic Value of Programmed Cell Death-Ligand 1 Expression in Tumor-Infiltrating Lymphocytes and Viral Load in Peripheral Blood Mononuclear Cells for Epsteinâ€“Barr Virusâ€“Positive Nasopharyngeal Carcinoma. Clinical Chemistry, 2020, 66, 1219-1227.	1.5	12
44	Targeted Radionuclide Therapy in Patient-Derived Xenografts Using 177Lu-EB-RGD. Molecular Cancer Therapeutics, 2020, 19, 2034-2043.	1.9	22
45	Optimal image guidance for tumor biopsy in non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2739-2740.	3.3	1
46	Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma. Nuclear Medicine and Biology, 2020, 86-87, 44-51.	0.3	6
47	Estrogen-ERÎ± signaling and DNA hypomethylation co-regulate expression of stem cell protein PIWIL1 in ERÎ±-positive endometrial cancer cells. Cell Communication and Signaling, 2020, 18, 84.	2.7	14
48	68Ga-FAPI PET/CT Improves Therapeutic Strategy by Detecting a Second Primary Malignancy in a Patient With Rectal Cancer. Clinical Nuclear Medicine, 2020, 45, 468-470.	0.7	17
49	Evaluation of the 8th edition of the American joint committee on cancerâ€™s pathological staging system in prognosis assessment and treatment decision making for stage T1-2N1 breast cancer after mastectomy. Breast, 2020, 51, 2-10.	0.9	13
50	Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1820-1832.	3.3	348
51	Circular RNA TUBD1 Acts as the miR-146a-5p Sponge to Affect the Viability and Pro-Inflammatory Cytokine Production of LX-2 Cells through the TLR4 Pathway. Radiation Research, 2020, 193, 383.	0.7	19
52	Development and validation of a radiomics signature on differentially expressed features of 18F-FDG PET to predict treatment response of concurrent chemoradiotherapy in thoracic esophagus squamous cell carcinoma. Radiotherapy and Oncology, 2020, 146, 9-15.	0.3	19
53	Is tubal endometriosis an asymmetric disease? A 17-year retrospective study. Archives of Gynecology and Obstetrics, 2020, 301, 721-727.	0.8	6
54	[68Ga]Ga-DOTA-FAPI-04 improves tumor staging and monitors early response to chemoradiotherapy in a patient with esophageal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3188-3189.	3.3	35

#	Article	IF	Citations
55	Concordance of PD-L1 Status Between Image-Guided Percutaneous Biopsies and Matched Surgical Specimen in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 551367.	1.3	4
56	Final results of a phase III randomized trial of comparison of three paclitaxel-based regimens concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 4564-4564.	0.8	0
57	Prognostic factors and treatment comparison in small cell neuroendocrine carcinoma of the uterine cervix in the surveillance, epidemiology, and end results database.. Journal of Clinical Oncology, 2020, 38, e18015-e18015.	0.8	0
58	Comparative study between image-guided percutaneous biopsies and matched surgical specimens for the evaluation of PD-L1 status in non-small cell lung cancer.. Journal of Clinical Oncology, 2020, 38, e15168-e15168.	0.8	0
59	Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: a case report and literature review. Translational Cancer Research, 2020, 9, 4457-4463.	0.4	3
60	Title is missing!. , 2020, 15, e0236841.		0
61	Title is missing!. , 2020, 15, e0236841.		0
62	Title is missing!. , 2020, 15, e0236841.		0
63	Title is missing!. , 2020, 15, e0236841.		0
64	The 1-year mortality after radiotherapy for nasopharyngeal carcinoma: a population-based analysis. Future Oncology, 2019, 15, 3357-3365.	1.1	2
65	MicroRNA-146a-5p Attenuates Fibrosis-related Molecules in Irradiated and TGF-beta1-Treated Human Hepatic Stellate Cells by Regulating PTPRA-SRC Signaling. Radiation Research, 2019, 192, 621.	0.7	18
66	Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma . Cancer Management and Research, 2019, Volume 11, 1631-1640.	0.9	9
67	Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation. Radiation Oncology, 2019, 14, 35.	1.2	33
68	Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial. Journal of Clinical Oncology, 2019, 37, 1695-1703.	0.8	99
69	A Nomogram for the Prediction of Prognosis in Patients With Distant Metastases of Nasopharyngeal Carcinoma. Frontiers in Oncology, 2019, 9, 240.	1.3	8
70	Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1485-1494.	3.3	31
71	The effect of histological subtypes on survival outcome in nasopharyngeal carcinoma after extensive follow up. Annals of Translational Medicine, 2019, 7, 768-768.	0.7	22
72	Safety results of a phase III randomized trial of comparison of three paclitaxel-based regimens concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma (ESO-Shanghai 2).. Journal of Clinical Oncology, 2019, 37, 4055-4055.	0.8	0

#	Article	IF	Citations
73	A multicenter prospective observational study of nutritional status on survival in locally advanced nasopharynx cancer treated by induction chemotherapy and chemoradiotherapy.. Journal of Clinical Oncology, 2019, 37, 6036-6036.	0.8	1
74	The Road Less Traveled: Should We Omit Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer?. Clinical Lung Cancer, 2018, 19, 289-293.	1.1	3
75	Out of the darkness and into the light: New strategies for improving treatments for locally advanced non-small cell lung cancer. Cancer Letters, 2018, 421, 59-62.	3.2	8
76	A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinomaâ€"the ESO-shanghai 1 trial protocol. Radiation Oncology, 2018, 13, 33.	1.2	11
77	Survival in signet ring cell carcinoma varies based on primary tumor location: a Surveillance, Epidemiology, and End Results database analysis. Expert Review of Gastroenterology and Hepatology, 2018, 12, 209-214.	1.4	50
78	Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2). BMJ Open, 2018, 8, e020785.	0.8	7
79	Dosimetric superiority of IMRT with jaw tracking technique for whole esophagus and T-shaped field radiotherapy in advanced esophageal cancer. PLoS ONE, 2018, 13, e0202628.	1.1	6
80	The Effect of Marital Status on Nasopharyngeal Carcinoma Survival: A Surveillance, Epidemiology and End Results Study. Journal of Cancer, 2018, 9, 1870-1876.	1.2	23
81	Prognostic significance of Ki67 expression and the derived neutrophil–lymphocyte ratio in nasopharyngeal carcinoma. Cancer Management and Research, 2018, Volume 10, 1919-1926.	0.9	16
82	Comparison of survival outcomes of locally advanced breast cancer patients receiving post-mastectomy radiotherapy with and without immediate breast reconstruction: a population-based analysis. Cancer Management and Research, 2018, Volume 10, 1993-2002.	0.9	9
83	Patterns of Distant Metastasis Between Histological Types in Esophageal Cancer. Frontiers in Oncology, 2018, 8, 302.	1.3	52
84	Effect of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy on nutritional status in locoregionally advanced nasopharyngeal carcinoma patients: A prospective observational study.. Journal of Clinical Oncology, 2018, 36, e18002-e18002.	0.8	0
85	Final results of a phase 3 study of comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in chemoradiotherapy for locally advanced esophageal carcinoma (ESO-Shanghai 1).. Journal of Clinical Oncology, 2018, 36, 4053-4053.	0.8	0
86	MicroRNA-204 suppressed proliferation and motility capacity of human hepatocellular carcinoma via directly targeting zinc finger E-box binding homeobox 2. Oncology Letters, 2017, 13, 3823-3830.	0.8	8
87	Intraoperative neuromonitoring loss in abnormal magnetic resonance imaging signal intensity from patients with cervical compressive myelopathy. Journal of the Neurological Sciences, 2017, 381, 235-239.	0.3	2
88	Demographic and clinicopathological characteristics of nasopharyngeal carcinoma and survival outcomes according to age at diagnosis: A population-based analysis. Oral Oncology, 2017, 73, 83-87.	0.8	40
89	Therapeutic role of axillary lymph node dissection in patients with stage IV breast cancer: a population-based analysis. Journal of Cancer Research and Clinical Oncology, 2017, 143, 467-474.	1.2	7
90	Dosimetric superiority of flattening filter free beams for single-fraction stereotactic radiosurgery in single brain metastasis. Oncotarget, 2017, 8, 35272-35279.	0.8	12

#	Article	IF	Citations
91	Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance. Oncotarget, 2017, 8, 113287-113293.	0.8	3
92	Safety results of a phase 3 study of comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in chemoradiotherapy for locally advanced esophageal carcinoma (ESO-Shanghai 1).. Journal of Clinical Oncology, 2017, 35, 4066-4066.	0.8	6
93	Patterns of distant metastasis in Chinese women according to breast cancer subtypes. Oncotarget, 2016, 7, 47975-47984.	0.8	23
94	Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet, The, 2016, 388, 1883-1892.	6.3	406
95	The preventative effect of Akt knockout on liver cancer through modulating NF-Î²B-regulated inflammation and Bad-related apoptosis signaling pathway. International Journal of Oncology, 2016, 48, 1467-1476.	1.4	10
96	Radiation plus concurrent nimotuzumab versus CDDP in locally advanced nasopharyngeal cancer: Results of a phase III randomised trial.. Journal of Clinical Oncology, 2016, 34, 6002-6002.	0.8	5
97	Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial.. Journal of Clinical Oncology, 2016, 34, 6007-6007.	0.8	1
98	Number of Negative Lymph Nodes Can Predict Survival after Postmastectomy Radiotherapy According to Different Breast Cancer Subtypes. Journal of Cancer, 2015, 6, 261-269.	1.2	3
99	Dosimetric Comparison of the Simultaneous Integrated Boost in Whole-Breast Irradiation after Breast-Conserving Surgery: IMRT, IMRT plus an Electron Boost and VMAT. PLoS ONE, 2015, 10, e0120811.	1.1	15
100	Anterior Subcutaneous versus Submuscular Transposition of the Ulnar Nerve for Cubital Tunnel Syndrome: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0130843.	1.1	13
101	Prognostic Value of Different Lymph Node Staging Methods in Esophageal Squamous Cell Carcinoma After Esophagectomy. Annals of Thoracic Surgery, 2015, 99, 284-290.	0.7	19
102	Number of negative lymph nodes is associated with disease-free survival in patients with breast cancer. BMC Cancer, 2015, 15, 43.	1.1	10
103	Postmastectomy Radiotherapy Improves Disease-Free Survival of High Risk of Locoregional Recurrence Breast Cancer Patients with T1-2 and 1 to 3 Positive Nodes. PLoS ONE, 2015, 10, e0119105.	1.1	22
104	Prognosis of patients with esophageal squamous cell carcinoma after esophagectomy using the log odds of positive lymph nodes. Oncotarget, 2015, 6, 36911-36922.	0.8	26
105	Distribution of metastatic disease in the brain in relation to the hippocampus: a retrospective single-center analysis of 6064 metastases in 632 patients. Oncotarget, 2015, 6, 44030-44036.	0.8	25
106	Using the Lymph Node Ratio to Evaluate the Prognosis of Stage II/III Breast Cancer Patients Who Received Neoadjuvant Chemotherapy and Mastectomy. Cancer Research and Treatment, 2015, 47, 757-764.	1.3	20
107	Prognostic Value of Ki-67 in Breast Cancer Patients with Positive Axillary Lymph Nodes: A Retrospective Cohort Study. PLoS ONE, 2014, 9, e87264.	1.1	33
108	Planning Study of Flattening Filter Free Beams for Volumetric Modulated Arc Therapy in Squamous Cell Carcinoma of the Scalp. PLoS ONE, 2014, 9, e114953.	1.1	3

#	Article	IF	Citations
109	The value of radiotherapy in breast cancer patients with isolated ipsilateral supraclavicular lymph node metastasis without distant metastases at diagnosis: a retrospective analysis of Chinese patients. OncoTargets and Therapy, 2014, 7, 281.	1.0	6
110	Post-mastectomy radiotherapy can improve survival in breast cancer patients aged 35 years or younger with four or more positive nodes but not in one to three positive nodes. Therapeutics and Clinical Risk Management, 2014, 10, 867.	0.9	3
111	Number of negative lymph nodes can predict survival of breast cancer patients with four or more positive lymph nodes after postmastectomy radiotherapy. Radiation Oncology, 2014, 9, 284.	1.2	12
112	Dosimetric analysis of the brachial plexus among patients with breast cancer treated with post-mastectomy radiotherapy to the ipsilateral supraclavicular area: report of 3 cases of radiation-induced brachial plexus neuropathy. Radiation Oncology, 2014, 9, 292.	1.2	16
113	Tumor location is a prognostic factor for survival of Chinese women with T1-2N0M0 breast cancer. International Journal of Surgery, 2014, 12, 394-398.	1.1	28
114	Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast, 2014, 23, 88-93.	0.9	90
115	Biological Response of Nasopharyngeal Carcinoma to Radiation Therapy: A Pilot Study Using Serial¹⁸F-FDG PET/CT Scans. Cancer Investigation, 2012, 30, 528-536.	0.6	15
116	Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor-Positive Breast Cancer without Chemotherapy-Induced Amenorrhea. Cancer Research and Treatment, 1970, 47, 55-63.	1.3	8